[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356109-105":59,"doc-detail-356109-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lipid-nanoparticle-co-delivery-of-mrna-and-a-small-molecule-drug-for-oral-cancer-chemoimmunotherapy","Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy","","Oral squamous cell carcinoma (OSCC) accounts for the majority of head and neck cancers and is marked by poor 5-year survival and an increasing incidence, driven by tumor suppressor gene inactivation/mutation and a “cold” tumor microenvironment. Current therapies are limited and often cause significant functional morbidity. A lipid nanoparticle platform co-encapsulating p53 mRNA and ciclopirox is used to promote caspase activation and to repolarize tumor-associated macrophages toward M1-like phenotypes. The combined formulation works across p53-therapy–susceptible and -resistant models and supports multiple mechanisms of OSCC progression and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lipid-nanoparticle-co-delivery-of-mrna-and-a-small-molecule-drug-for-oral-cancer-chemoimmunotherapy/356109/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lipid-nanoparticle-co-delivery-of-mrna-and-a-small-molecule-drug-for-oral-cancer-chemoimmunotherapy/356109.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is oral squamous cell carcinoma (OSCC) difficult to treat?","Question",{"text":112,"@type":113},"OSCC features frequent tumor suppressor gene inactivation and a “cold” tumor microenvironment that supports immune evasion. Standard and targeted therapies have limited response rates and can be associated with substantial functional morbidity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic strategy does the lipid nanoparticle platform use?",{"text":117,"@type":113},"The platform co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX). It is designed to deliver both agents together to affect multiple mechanisms of OSCC progression.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the co-delivery approach influence the tumor microenvironment?",{"text":121,"@type":113},"Both drugs facilitate caspase activation and help create a less immunosuppressive TME. This includes repolarizing tumor-associated macrophages toward M1-like phenotypes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356109,1790513044,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Advanced Materials  \n[www.advmat.de](www.advmat.de)  \n RESEARCH ARTICLE   \nLipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy  \nMarshall S. Padilla1   Jacqueline J. Li1  Qunzhou Zhang2   Korey Patwari1  Shihong Shi2   \nHannah M. Yamagata1  Ryann A. Joseph1  Briyanna N. Hymms1 Ori Z. Chalom1  Kushol Gupta3  Mohamad-Gabriel Alameh4, 5   \n Sridatta V. Teerdhala1  Drew Weissman4, 5   \n Emily Fitzgerald1  Anh D. Le2, 6   \nMichael J. Mitchell1, 4, 7, 8, 9, 10, 11  \n1 Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA  2 Department of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania School of Dental Medicine, Philadelphia, Pennsylvania, USA  3 Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  4 Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  5 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  6 Department of Oral & Maxillofacial Surgery, Penn Medicine Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA  7Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  8Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  9 Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  10Institute for Regenerative Medicine, Perelman School of Medicine, University of  \nPennsylvania, Philadelphia, Pennsylvania, USA  11 Center for Precision Engineering for Health, University of Pennsylvania, Philadelphia, Pennsylvania, USA Correspondence: Anh D. Le ([anh.le@pennmedicine.upenn.edu](anh.le@pennmedicine.upenn.edu))  Michael J. Mitchell (mjmitch@seas.upenn.edu)  \nReceived: 8 December 2025  Revised: 2 June 2026  Accepted: 9 June 2026  \nKeywords: lipid nanoparticles | mRNA therapy | oral squamous cell carcinoma | tumor-associated macrophages  \nABSTRACT  \nOral squamous cell carcinoma (OSCC) represents 90% of all head and neck cancers. Despite decades of research, the 5-year survival rate is 50% . Strikingly, the overall incidence rate is projected to increase by 30% in the next 10 years, which may result ina sharp increase in mortality. Two fundamental aspects of OSCC are that it progresses via the inactivation and mutation of tumor suppressor genes (TSGs) and has a “cold” tumor microenvironment (TME). A major barrier in the treatment of OSCC is the lack of novel therapies clinicians have at their disposal that are designed to disrupt tumor progression by reshaping the cold tumors into inflammatory “hot” tumors. To overcome these obstacles, we employed a lipid nanoparticle (LNP) that co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX). We demonstrate that both drugs have innate chemotherapeutic properties by facilitating caspase activation. Moreover, these therapies can create a less immunosuppressive TME in part by repolarizing tumor-associated macrophages (TAMs) to M1-like phenotypes. When formulated together, our platform provides an all-in-one approach for OSCC, effective in both p53-therapy-susceptible and p53-therapy-resistant models. Additionally, this work offers a template for a delivery platform capable of tackling multiple mechanisms of OSCC progression and survival.  \n1  Introduction  \nHead and neck squamous cell carcinoma (HNSCC) is the sixth most common form of cancer in the world. Approximately 450 000 people die from this disease each year, with oral squa-  \nmous cell carcinoma (OSCC) representing over 90% of HNSCC [1] . Unfortunately, the incidence rate of OSCC is projected to increase by 30% by the end of the decade. Standard of care for OSCC involves ablative surgery and radiation,","cbCaimG6jTmw1aHj","https://ap.wps.com/l/cbCaimG6jTmw1aHj","pdf",6444228,"English","# Introduction\n## Background on oral squamous cell carcinoma and limitations of current therapies\n## Rationale for targeted chemoimmunotherapy and tumor microenvironment modulation\n## Role of tumor-associated macrophages in immune evasion","[{\"question\":\"Why is oral squamous cell carcinoma (OSCC) difficult to treat?\",\"answer\":\"OSCC features frequent tumor suppressor gene inactivation and a “cold” tumor microenvironment that supports immune evasion. Standard and targeted therapies have limited response rates and can be associated with substantial functional morbidity.\"},{\"question\":\"What therapeutic strategy does the lipid nanoparticle platform use?\",\"answer\":\"The platform co-encapsulates p53 mRNA and the small molecule ciclopirox (CPX). It is designed to deliver both agents together to affect multiple mechanisms of OSCC progression.\"},{\"question\":\"How does the co-delivery approach influence the tumor microenvironment?\",\"answer\":\"Both drugs facilitate caspase activation and help create a less immunosuppressive TME. This includes repolarizing tumor-associated macrophages toward M1-like phenotypes.\"}]","Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy | PDF",1790123432,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53a41eeccb4620e05da88e372027fa62.webp",983,1283,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/852ab36abb79d503b15dbea6ad4607c5.webp",982,1281,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23dc299e9c2148d183eb4f93f479b109.webp",981,1280,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7da34a014fa0585e84a90055abda96d8.webp",980,1279]